130 related articles for article (PubMed ID: 34194431)
1. c-Rel Is Required for IL-33-Dependent Activation of ILC2s.
Zaini A; Fulford TS; Grumont RJ; Runting J; Rodrigues G; Ng J; Gerondakis S; Zaph C; Scheer S
Front Immunol; 2021; 12():667922. PubMed ID: 34194431
[TBL] [Abstract][Full Text] [Related]
2. SLAM-family receptors promote resolution of ILC2-mediated inflammation.
Wang Y; Quan Y; He J; Chen S; Dong Z
Nat Commun; 2024 Jun; 15(1):5056. PubMed ID: 38871792
[TBL] [Abstract][Full Text] [Related]
3. HTR2A agonists play a therapeutic role by restricting ILC2 activation in papain-induced lung inflammation.
Wang Z; Yan C; Du Q; Huang Y; Li X; Zeng D; Mao R; Gurram RK; Cheng S; Gu W; Zhu L; Fan W; Ma L; Ling Z; Qiu J; Li D; Liu E; Zhang Y; Fang Y; Zhu J; Sun B
Cell Mol Immunol; 2023 Apr; 20(4):404-418. PubMed ID: 36823235
[TBL] [Abstract][Full Text] [Related]
4. The neuropeptide neuromedin U stimulates innate lymphoid cells and type 2 inflammation.
Klose CSN; Mahlakõiv T; Moeller JB; Rankin LC; Flamar AL; Kabata H; Monticelli LA; Moriyama S; Putzel GG; Rakhilin N; Shen X; Kostenis E; König GM; Senda T; Carpenter D; Farber DL; Artis D
Nature; 2017 Sep; 549(7671):282-286. PubMed ID: 28869965
[TBL] [Abstract][Full Text] [Related]
5. ILC2 require cell-intrinsic ST2 signals to promote type 2 immune responses.
Topczewska PM; Rompe ZA; Jakob MO; Stamm A; Leclère PS; Preußer A; Duerr CU; Thole LML; Kotsch K; Artis D; Klose CSN
Front Immunol; 2023; 14():1130933. PubMed ID: 37063913
[TBL] [Abstract][Full Text] [Related]
6. NRP1 downregulation correlates with enhanced ILC2 responses during IL-33 challenge.
Wang Y; Liu G; Wang J; Zhou P; Zhang L; Liu Q; Zhou J
Immunology; 2024 Jun; 172(2):226-234. PubMed ID: 38409805
[TBL] [Abstract][Full Text] [Related]
7. ILC2-driven innate immune checkpoint mechanism antagonizes NK cell antimetastatic function in the lung.
Schuijs MJ; Png S; Richard AC; Tsyben A; Hamm G; Stockis J; Garcia C; Pinaud S; Nicholls A; Ros XR; Su J; Eldridge MD; Riedel A; Serrao EM; Rodewald HR; Mack M; Shields JD; Cohen ES; McKenzie ANJ; Goodwin RJA; Brindle KM; Marioni JC; Halim TYF
Nat Immunol; 2020 Sep; 21(9):998-1009. PubMed ID: 32747815
[TBL] [Abstract][Full Text] [Related]
8. Adiponectin restrains ILC2 activation by AMPK-mediated feedback inhibition of IL-33 signaling.
Wang L; Luo Y; Luo L; Wu D; Ding X; Zheng H; Wu H; Liu B; Yang X; Silva F; Wang C; Zhang X; Zheng X; Chen J; Brigman J; Mandell M; Zhou Z; Liu F; Yang XO; Liu M
J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33104171
[TBL] [Abstract][Full Text] [Related]
9. A novel type-2 innate lymphoid cell-based immunotherapy for cancer.
Saranchova I; Xia CW; Besoiu S; Finkel PL; Ellis SLS; Kari S; Munro L; Pfeifer CG; Fazli L; Gleave ME; Jefferies WA
Front Immunol; 2024; 15():1317522. PubMed ID: 38524132
[TBL] [Abstract][Full Text] [Related]
10. The neuropeptide NMU amplifies ILC2-driven allergic lung inflammation.
Wallrapp A; Riesenfeld SJ; Burkett PR; Abdulnour RE; Nyman J; Dionne D; Hofree M; Cuoco MS; Rodman C; Farouq D; Haas BJ; Tickle TL; Trombetta JJ; Baral P; Klose CSN; Mahlakõiv T; Artis D; Rozenblatt-Rosen O; Chiu IM; Levy BD; Kowalczyk MS; Regev A; Kuchroo VK
Nature; 2017 Sep; 549(7672):351-356. PubMed ID: 28902842
[TBL] [Abstract][Full Text] [Related]
11. PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity.
Helou DG; Shafiei-Jahani P; Lo R; Howard E; Hurrell BP; Galle-Treger L; Painter JD; Lewis G; Soroosh P; Sharpe AH; Akbari O
Nat Commun; 2020 Aug; 11(1):3998. PubMed ID: 32778730
[TBL] [Abstract][Full Text] [Related]
12. Gut Microbiota Regulate Gut-Lung Axis Inflammatory Responses by Mediating ILC2 Compartmental Migration.
Pu Q; Lin P; Gao P; Wang Z; Guo K; Qin S; Zhou C; Wang B; Wu E; Khan N; Xia Z; Wei X; Wu M
J Immunol; 2021 Jul; 207(1):257-267. PubMed ID: 34135060
[TBL] [Abstract][Full Text] [Related]
13. Cyclic-di-GMP Induces STING-Dependent ILC2 to ILC1 Shift During Innate Type 2 Lung Inflammation.
Cavagnero KJ; Badrani JH; Naji LH; Amadeo MB; Leng AS; Lacasa LD; Strohm AN; Renusch SR; Gasparian SS; Doherty TA
Front Immunol; 2021; 12():618807. PubMed ID: 33679760
[TBL] [Abstract][Full Text] [Related]
14. Alternative activation generates IL-10 producing type 2 innate lymphoid cells.
Seehus CR; Kadavallore A; Torre B; Yeckes AR; Wang Y; Tang J; Kaye J
Nat Commun; 2017 Dec; 8(1):1900. PubMed ID: 29196657
[TBL] [Abstract][Full Text] [Related]
15. Piezo1 channels restrain ILC2s and regulate the development of airway hyperreactivity.
Hurrell BP; Shen S; Li X; Sakano Y; Kazemi MH; Quach C; Shafiei-Jahani P; Sakano K; Ghiasi H; Akbari O
J Exp Med; 2024 May; 221(5):. PubMed ID: 38530239
[TBL] [Abstract][Full Text] [Related]
16. BATF promotes group 2 innate lymphoid cell-mediated lung tissue protection during acute respiratory virus infection.
Wu X; Kasmani MY; Zheng S; Khatun A; Chen Y; Winkler W; Zander R; Burns R; Taparowsky EJ; Sun J; Cui W
Sci Immunol; 2022 Jan; 7(67):eabc9934. PubMed ID: 35030033
[TBL] [Abstract][Full Text] [Related]
17. Iron controls the development of airway hyperreactivity by regulating ILC2 metabolism and effector function.
Hurrell BP; Sakano Y; Shen S; Helou DG; Li M; Shafiei-Jahani P; Kazemi MH; Sakano K; Li X; Quach C; Barbers R; Akbari O
Sci Transl Med; 2024 May; 16(746):eadk4728. PubMed ID: 38718131
[TBL] [Abstract][Full Text] [Related]
18. Dietary Fiber-Induced Microbial Short Chain Fatty Acids Suppress ILC2-Dependent Airway Inflammation.
Lewis G; Wang B; Shafiei Jahani P; Hurrell BP; Banie H; Aleman Muench GR; Maazi H; Helou DG; Howard E; Galle-Treger L; Lo R; Santosh S; Baltus A; Bongers G; San-Mateo L; Gilliland FD; Rehan VK; Soroosh P; Akbari O
Front Immunol; 2019; 10():2051. PubMed ID: 31620118
[TBL] [Abstract][Full Text] [Related]
19. LKB1 prevents ILC2 exhaustion to enhance antitumor immunity.
Niu H; Zhang H; Wang D; Zhao L; Zhang Y; Zhou W; Zhang J; Su X; Sun J; Su B; Qiu J; Shen L
Cell Rep; 2024 May; 43(5):113579. PubMed ID: 38670109
[TBL] [Abstract][Full Text] [Related]
20. Type 2 innate lymphoid cells are not involved in mouse bladder tumor development.
Schneider AK; Domingos-Pereira S; Cesson V; Polak L; Fallon PG; Zhu J; Roth B; Nardelli-Haefliger D; Derré L
Front Immunol; 2023; 14():1335326. PubMed ID: 38283350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
